|
|
Upfront Briefing
J&J put real money down: a $2.58B path to Sail Biomedicines, $785M of it upfront, for a swing at in vivo CAR-T in autoimmune. Elsewhere, Capricor's deramiocel walked into a very public 9-3 reality check at adcomm. Capital markets keep finding side doors — Caldera and Vidya combined for $478M into Nasdaq shells via reverse mergers, no IPO window required. A deferred mega-option, a regulatory gut-punch, and a back-door listing, all before your second coffee.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,316.2 |
(1.5%) |
6.7% |
| Nasdaq 100 |
27,192.3 |
(2.1%) |
7.9% |
| Russell 2000 |
2,906.3 |
(1.6%) |
15.9% |
| Healthcare (XLV) |
166.2 |
(0.6%) |
6.9% |
| Biotech (XBI) |
147.9 |
(1.2%) |
21.7% |
| Nasdaq Biotech (NBI) |
6,521.3 |
(1.0%) |
14.3% |
| Clinical Trials (BBC) |
48.4 |
(0.8%) |
28.7% |
|
- Healthcare and biotech outperformed a broad selloff — XLV off 0.6% and XBI down 1.2% against the S&P 500's 1.5% drop — with sector attention on J&J's $2.58B in vivo CAR-T option for Sail and Capricor's 9-3 adcomm rebuke of deramiocel rather than the macro tape.
- The broad risk-off came off a hawkish Fed hold: the FOMC left rates at 3.50%–3.75% on July 29 with three dissents favoring a hike, driving the 10-year yield to ~4.70% and the 30-year past 5.2%, while Iran's missile strike on U.S. forces pushed crude up ~7% and a semiconductor rout tipped the Nasdaq 100 into correction.
- Market data: U.S. cash close Wednesday, 29 July 2026.
The Big 3
|
1
|
J&J sets $2.58B option deal for Sail Biomedicines
|
- Sail Biomedicines' in vivo CAR-T platform landed a $2.58B option structure from Johnson & Johnson, including $785M in initial payments ($465M of it equity) plus up to $140M in milestones, with the acquisition option deferred until the data matures.
- Why it matters: The structure matters as much as the size: $785M in initial payments (including a $465M equity stake) and up to $140M in milestones buy J&J a look at Sail's in vivo CAR-T platform in autoimmune, while the $2.58B acquisition option defers the real capital until the data reads out. J&J trimmed 2026 adjusted EPS guidance by $0.18 on the deal and shares slipped ~1.6% after hours. For Flagship, it's fresh validation of in vivo reprogramming — and a live comp for other in vivo CAR-T names (Interius, Umoja, Kelonia) shopping for partners. The gate: the platform is early, and the option lets J&J walk.
- Source: STAT
- More: Endpoints; BioSpace
|
|
2
|
FDA panel votes 9-3 against Capricor's deramiocel
|
- Capricor's deramiocel in Duchenne muscular dystrophy took a 9-3 FDA advisory committee loss, with disputed efficacy analyses and cardiac endpoints front and center.
- Why it matters: A 9-3 vote against deramiocel materially raises approval risk and likely forces investors to discount commercialization odds more aggressively. The panel's focus on efficacy analyses and cardiac endpoints also raises the evidentiary bar for other rare-disease developers trying to bridge thin datasets into approval.
-
Source:
BioSpace
- More: STAT; BioPharma Dive; Fierce Biotech
|
| 3 | Caldera, Vidya raise $478M in reverse merger deals |
- Caldera Therapeutics and Vidya Therapeutics raised $478M collectively through reverse go-public mergers — Caldera into Synlogic's Nasdaq shell, Vidya into Processa — showing the alternative-IPO plumbing is still very much open.
- Why it matters: Two reverse mergers in a single day is the clearest sign yet that private biotechs are routing around a still-shut IPO window. Caldera pairs Synlogic's shell with a $278M concurrent placement (Bain Capital Life Sciences, TCGX, Atlas, venBio, Blackstone) to fund Phase 2 of CLD-423, a TL1A x IL-23p19 bispecific licensed from Qyuns that squares up against AbbVie's Skyrizi and Merck's tulisokibart. The read for crossover funds: a dormant Nasdaq listing is the exit of choice when the traditional door stays jammed. The catch — shell math is dilutive and cash-dependent, and CLD-423 has only Phase 1 data, due by year-end.
- Source: BioSpace
- More: Endpoints; Fierce Biotech
|
Everything Else that broke
- Sanofi posted double-digit Q2 sales growth and upgraded 2026 guidance. — PR
- Ipsen reported strong H1 results and lifted full-year guidance. — PR
- Idorsia said QUVIVIQ sales rose 62% year over year. — PR
- Biogen struck a cautious tone on diranersen despite tau validation in Alzheimer's. — BioSpace
- Dasher completed Phase 2 enrollment for YA-101 in multiple system atrophy, with top-line data expected in Q1 2027. — BioSpace
- Bausch Health raised guidance after Q2 revenue reached $2.85B. — PR
- Latigo reported positive Phase 2 data for LTG-001 in acute pain. — STAT
- FDA accepted Dyne's z-rostudirsen BLA and set a Jan. 21, 2027 PDUFA. — PR
- The EU authorized Pfizer-BioNTech's XFG-adapted COVID vaccine for the 2026-2027 formula. — PR
- Viking fully enrolled Phase 3 VANQUISH 1 and 2 for obesity drug VK2735. — PR
- 60 Degrees hit minimum enrollment in its hospitalized babesiosis study. — PR
- The FTC sued Hims & Hers over health-data sharing and billing practices. — STAT
- The US released $600M in funding for Gavi. — Reuters
- Merck briefly posted, then pulled, a trial plan pairing its PD-1xVEGF bispecific with a TROP2 ADC — the first concrete hint of its late-stage strategy in the class. — Fierce Biotech
- A judge declined to dismiss the investor suit over Novo Nordisk's CagriSema readout, letting the securities case proceed. — Fierce Biotech
- CellCentric secured up to $140M in non-dilutive financing from HealthCare Royalty to advance inobrodib toward registrational development. — Business Wire
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
Ember LifeSciences and Alfresa formed a capital and business alliance around Japan's pharmaceutical cold chain. — PR
- Healthcare Triangle signed a non-binding LOI to buy 51% of CosmoInnovations. — PR
- Vertex paid AbCellera $28M upfront — plus undisclosed milestones and tiered royalties — for a multispecific T-cell engager collaboration led by autoimmune disease. — Fierce Biotech
VC / Private Financings
- No notable VC / private financings in the last 24 hours.
IPOs / Follow-Ons
- INOVIO priced a $20M public offering. — PR
- Caldera Therapeutics to go public via reverse merger with Synlogic, paired with a $278M private placement. — Fierce Biotech
- Vidya Therapeutics to go public via reverse merger with Processa, advancing a BTK inhibitor. — Fierce Biotech
Academic Corner - ProteinGuide showed on-the-fly property conditioning for pretrained protein generative models. — Nature Biotech
- A Nature Medicine study flagged histidine as a potentially modifiable biomarker for cancer risk stratification. — Nature Medicine
|
That's the brief — J&J deferred the check, the FDA panel didn't, and two biotechs slipped in the back door. — BioBucks Team
|
|
|
